

Appendix 2. Characteristics of Included Systematic Reviews

Systematic Review	Core Topic	Subgroup	Number of RCTs	Number Observational Studies	Total Patients	Total RCT Patients	Meta-analyses	Modified AMSTAR Score
King 2014	Primary Care	Not Applicable	0	47	NR	0	N	2
Lagisetty 2017	Primary Care	Not Applicable	10	25	7924	NR	N	5
Maree 2016	Primary Care	Not Applicable	1	14	NR	NR	N	4
Simoens 2005	Primary Care	Not Applicable	45	NR	NR	N	N	3
Argoff 2013	Diagnosis	Not Applicable	0	50	NR	0	N	1
Balbale 2017	Diagnosis	Not Applicable	0	12	1884	0	N	4
Becker 2013	Diagnosis	Not Applicable	0	14	1754	0	N	5
Blanchard 2016	Diagnosis	Not Applicable	0	14	2278	0	N	2
Canan 2017	Diagnosis	Not Applicable	0	15	190 - 2.3million	0	N	4
Chou 2009	Diagnosis	Not Applicable	0	16	2136	0	N	4
Cochran 2015	Diagnosis	Not Applicable	0	7	134603	0	N	4
Dowell 2016	Diagnosis	Not Applicable	0	6	1339	0	N	5
Lawrence 2017	Diagnosis	Not Applicable	0	34	5234	0	N	6
Shmulewitz 2015	Diagnosis	Not Applicable	0	NR	11458	0	N	2
Smith 2013	Diagnosis	Not Applicable	0	11	NR	0	N	2

Smith 2015	Diagnosis	Not Applicable	0	6	1036	0	N	2
Solanki 2011	Diagnosis	Not Applicable	0	5	~5000	0	N	2
Turk 2008	Diagnosis	Not Applicable	0	9	16420	0	N	3
Mattick 2014	Pharmacotherapy	Buprenorphine	31	0	5430	5430	Y	6
Neilsen 2016	Pharmacotherapy	Buprenorphine	6	0	607	607	Y	6
Mattick 2009	Pharmacotherapy	Methadone	11	0	1969	1969	Y	6
Jarvis 2018	Pharmacotherapy	Naltrexone (injectable)	12	6	NR	NR	Y	4
Minozzi 2011	Pharmacotherapy	Naltrexone (oral)	13	0	1158	1158	Y	6
Frank 2017	Tapering (Duration of Therapy)	Not Applicable	11	56	12546	NR	N	5
Gowing 2017	Tapering (Duration of Therapy)	Not Applicable	27	0	3048	3048	Y	5
Amato 2011	Psychosocial	All Psychosocial Interventions	35	0	4319	4319	Y	6
Chou 2016	Psychosocial	All Psychosocial Interventions	28 included (study design not reported)		NR	NR	N	4
Gilchrist 2017	Psychosocial	All Psychosocial Interventions	32	0	12840	12840	Y	6
Timko 2016	Psychosocial	All Psychosocial Interventions	55 included (study design not reported)		NR	NR	N	4
DiClemente 2017	Psychosocial	Motivational Interviewing	34 included (study design not reported)		NR	NR	N	3

Ainscough	Psychosocial	Contingency Management	22	0	2333	2333	Y	4
Davis 2016	Psychosocial	Contingency Management	69 included (study design not reported)		NR	NR	N	1
Dugosh 2016	Psychosocial	Contingency Management	27 included (study design not reported)		NR	NR	N	2
Saulle 2017	Prescribing Practices	Witnessed Ingestion	4	2	7999	707	Y	6
Chou 2014	Prescribing Practices	Urine Drug Screening	0	1	2378	0	N	5
Taveros 2016	Comorbidities	Acute Pain	0	7	142	0	N	5
Morasco 2011	Comorbidities	Chronic Pain	0	38	NR	0	N	5
Hassan 2017	Comorbidities	Anxiety	22	0	1416*	1416	Y	6

*From 19/22 studies reported in systematic review

